This is a prospective, open label, dose escalating, multicenter, phase I study measuring the safety, tolerability, and pharmakokinetics of PankoMab-GEX™ after intravenous administration in patients with locally advanced or metastatic solid cancers refractory to standard treatment. The effect of PankoMab-GEX™ on the development of antibodies and tumor response will also be evaluated.